Login / Signup

Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN.

Stacie BellJoseph F MerolaDan E WebsterStephen R PenningtonWilson LiaoAlexis OgdieOliver FitzGeraldChristopher RitchlinJose U Scher
Published in: Current rheumatology reports (2020)
Program projects have recently identified areas of knowledge gaps in diagnosis, treatment, and prevention of psoriasis and psoriatic arthritis (PsA). NPF's Psoriasis Prevention Initiative aims to identify interventions that can prevent the onset and relapse of psoriatic disease or related comorbidities. The Psorcast Study is a joint venture between PPACMAN and Sage Bionetworks based on patient-generated smartphone measurements of psoriatic disease. Similarly, GRAPPA is involved in a number of projects related to axial PsA, enthesitis prevalence, and biomarker discoveries. As important initiatives bring new targets for diagnosis and therapeutics in psoriatic disease, supra-endeavors such as the NIH-Accelerating Medicines Partnership (AMP) and the European Innovative Medicines Initiative (IMI) are promising public-private partnerships that can significantly catapult the field forward.
Keyphrases
  • quality improvement
  • rheumatoid arthritis
  • prostate cancer
  • healthcare
  • ankylosing spondylitis
  • disease activity
  • radical prostatectomy
  • mental health
  • case report
  • electronic health record